"Pills or injections" sounds like a comfort question — needles versus no needles. It is actually three questions stacked together: which medications you are choosing between, what results each format has demonstrated, and what each costs. Answer those three and the comfort question usually answers itself.
What's Actually in Each Format
The injectable side is the famous one: weekly GLP-1 pens — semaglutide (Wegovy®) and tirzepatide (Zepbound®) — plus daily liraglutide. The FDA-approved oral side, per NIDDK's medication list, includes orlistat (a fat-absorption blocker), phentermine-topiramate (an appetite-suppressant combination), and naltrexone-bupropion (acting on appetite and reward pathways). Telehealth programs also sell compounded oral semaglutide — worth noting separately, because the landmark semaglutide trial evidence comes from the injectable form, not compounded tablets.
The Results Gap, Honestly Stated
The injectables hold the headline numbers: an average 14.9% body-weight reduction at 68 weeks for semaglutide in STEP 1, and up to 20.9% at 72 weeks for tirzepatide in SURMOUNT-1, both alongside lifestyle intervention. The approved oral medications produce more modest averages — meaningful for many patients, but not in the same range. If maximum effect is the priority and you are eligible, the injection is the evidence-backed answer. If a moderate goal, needle aversion, or budget points to pills, that is a legitimate clinical path — just one with calibrated expectations.
Side Effects Differ by Mechanism, Not Format
Neither format is the "gentle" one — each medication carries its own profile. GLP-1 injections front-load gastrointestinal effects around dose increases. Orlistat's effects are digestive and diet-dependent. The appetite-suppressant combinations carry their own exclusions — NIDDK notes conditions like glaucoma and hyperthyroidism for phentermine-topiramate. The practical takeaway: you are choosing a mechanism and its trade-offs, and that mapping against your medical history is precisely the prescriber's job.
Cost and Logistics
Generic oral medications are generally the cheapest prescription route. Brand-name injectables are the most expensive without coverage, with compounded injectables in between — typically a few hundred dollars monthly through telehealth programs. Logistics differ too: pills mean daily adherence and easy storage; weekly injections mean refrigeration and injection-day routine but only four adherence events a month. Pick the failure mode you are least likely to hit — a missed daily pill and a skipped weekly injection are different risks for different personalities.
The Bottom Line
Injections win on demonstrated effect size; pills win on cost, familiarity, and needle-free convenience — and both require the same things: eligibility, a licensed prescriber, and lifestyle change doing the foundational work. Decide your goal size and budget first, then let the clinician match the mechanism. Our pill program comparison and GLP-1 injection comparison cover the provider side of each path.
Sources used for medical context
- NIDDK for the approved oral medication list and exclusion notes.
- STEP 1 trial (PMID 33567185) for semaglutide outcomes.
- SURMOUNT-1 summary (ACC) for tirzepatide outcomes.
